FGAM
KPTI icon

Financial Gravity Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

Financial Gravity Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3
Closed -$75 – 1633
2024
Q1 		$75 Buy
+3
New +$53 ﹤0.01% 999
2023
Q4 		– Hold
0
– – – 1337

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Financial Gravity Asset Management's KPTI Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 3 shares — an estimated $75 sold.

Financial Gravity Asset Management first reported a position in KPTI in Q1 2024 and held it in 1 quarter. The position peaked at $75 in Q1 2024. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 3 Karyopharm Therapeutics shares in Q2 2024, an estimated $75.
  • Financial Gravity Asset Management first reported a position in Karyopharm Therapeutics in Q1 2024 and held it in 1 quarter.
  • Financial Gravity Asset Management's Karyopharm Therapeutics position peaked at $75 in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.